Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 4
The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC
Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.
Video content above is prompted by the following:
Quality of Life Considerations
Key Themes:
- Balance of Efficacy and Toxicity: Weighing survival benefits against treatment-related adverse events
- Patient Preferences: Discussion of Asian study data showing some patients prefer monotherapy with potentially shorter survival over combination therapy
- Prophylactic Management: Importance of supportive care measures to mitigate toxicity
Notable Insights:
- Dr Dietrich: “Quality of life is important when it comes to treatment-related toxicity. But...a significant drop occurs at the time of cancer progression, and that’s probably the quality-of-life impairment that I’m most struggling with.” He argued that quality and quantity of life often align rather than contradict.
- Dr Piotrowska: Highlighted the importance of supportive care data, noting “we’re seeing a lot of data from studies looking at ways to support patients better” including the COCOON study for dermatologic toxicities and the SKIPPirr regimen for preventing infusion-related reactions.
Related Content:
